An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy

2025-521642-14-00 · tracked via the Priya Life Science EU tracker

Sponsor

Teva Branded Pharmaceutical Products R&D LLC

Sponsor type

Pharmaceutical company

Therapeutic area

Nervous System Diseases

Decision date

04/02/2026

Enrollment target

149

Sites

France, Germany, Italy, Spain

Condition studied

Multiple System Atrophy

Investigational medicinal product(s)

Emrusolmin

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

The primary safety and tolerability endpoints are as follows: • number (%) of participants experiencing an adverse event, The primary safety and tolerability endpoints are as follows: • number (%) of participants who withdraw from the trial due to an adverse event

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521642-14-00 on CTIS ↗ ← All trials in the EU